Leukemia, a type of blood cancer that originates in the bone marrow, is characterized by uncontrolled growth abnormal cells, which disrupt normal functioning cells. Chimeric antigen receptor (CAR) T-cell treatment, form immunotherapy, utilizes genetically modified T cells to specifically target and eliminate This treatment has shown promising results for leukemia patients who are unresponsive c...

Abstract Genetic engineering of T-cells using chimeric antigen receptors (CARs) has shown promise in the treatment relapsed/refractory B-cell leukemia. However, a significant percentage patients will eventually relapse, often due to emergence tumor cells expressing low levels target antigen. Previous research demonstrated that hinge domain CAR plays crucial role regulating cytotoxic capabilitie...

By generating phosphorylcholine (PC)-specific, wild-type (mu), and chimeric (mu-I-A alpha) antigen receptor transfectants of mature B cells, we have shown that the COOH terminus of the mu heavy chain is essential for three major functions: immediate signal transduction (measured as changes in intracellular Ca2+), antigen presentation, and induction of immunoglobulin M secretion. A more detailed...

Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antig...

There is no vaccine to prevent dengue fever, a mosquito-borne viral disease, caused by four serotypes of dengue viruses. In this study, which has been prompted by the emergence of dengue virus envelope domain III as a promising sub-unit vaccine candidate, we have examined the possibility of developing a chimeric bivalent antigen with the potential to elicit neutralizing antibodies against two s...

Chimeric antigen receptors (CARs) are a breakthrough in genetic engineering that have revolutionized the field of adoptive cellular therapy (ACT). Cells expressing these rerouted to predefined target by inclusion an antigen-specific binding region within synthetic CAR construct. The advantage cells with programmed specificity has been demonstrated clinically oncology, and it is clear such great...

Whereas approximately half of metastatic melanoma patients benefit from combined immune checkpoint inhibition targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed cell death 1 (PD-1), for those who do not respond, further strategies treatment options need to be developed. Thus, focus is turning the use chimeric antigen receptor (CAR) T cells, a novel therapy that has ye...